Ritlecitinib ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎6

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003702-42-ES
(EUCTR)
17/05/202212/05/2022A Phase 3 Placebo-controlled Efficacy and Safety Study with Ritlecitinib (PF-06651600) in Adults with Moderately to Severely Active UCAN INTERVENTIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Moderate to Severe Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Ritlecitinib
Product Code: PF-06651600
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600
Product Name: Ritlecitinib
Product Code: PF-06651600
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600
Pfizer Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
432Phase 3Serbia;United States;Taiwan;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India;France;Denmark;Australia;South Africa;Netherlands;China;Korea, Republic of;Czechia;Turkey;Austria;United Kingdom;Mexico;Canada;Argentina;Belgium;Brazil;Poland;Bulgaria;Norway;Germany;Japan;Sweden
2EUCTR2016-003708-29-BG
(EUCTR)
20/04/201817/01/2018Study to evaluate the effectiveness of oral PF-06651600 and PF-06700841 in subjects with moderate to severe ulcerative colitis, a disease characterized by continuous inflammation that is localized to the colonA Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis - Vibrato Moderate to severe Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Ritlecitinib 10 mg
Product Code: PF-06651600 10 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Ritlecitinib 50 mg
Product Code: PF-06651600 50 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Ritlecitinib 5 mg
Product Code: PF-06700841 5 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Product Name: Brepocitinib 25 mg
Product Code: PF-06700841 25 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
318Phase 2Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Lithuania;Turkey;Austria;Israel;Russian Federation;Italy;Hungary;Canada;Poland;Romania;Denmark;Bulgaria;Georgia;Netherlands;Germany;Korea, Republic of
3EUCTR2016-003708-29-DE
(EUCTR)
07/08/201724/04/2017A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis - Vibrato A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis - Vibrato Moderate to severe Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Ritlecitinib 10 mg
Product Code: PF-06651600 10 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Ritlecitinib 50 mg
Product Code: PF-06651600 50 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Brepocitinib 5 mg
Product Code: PF-06700841 5 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Product Name: Brepocitinib 25 mg
Product Code: PF-06700841 25 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
318Phase 2Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Lithuania;Turkey;Austria;Israel;Russian Federation;Italy;Hungary;Canada;Poland;Romania;Denmark;Georgia;Bulgaria;Netherlands;Germany;Korea, Republic of
4EUCTR2016-003708-29-DK
(EUCTR)
27/06/201721/04/2017Study to evaluate the effectiveness of oral PF-06651600 and PF-06700841 in subjects with moderate to severe ulcerative colitis, a disease characterized by continuous inflammation that is localized to the colonA Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis - Vibrato Moderate to severe Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Ritlecitinib 10 mg
Product Code: PF-06651600 10 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Ritlecitinib 50 mg
Product Code: PF-06651600 50 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Brepocitinib 5 mg
Product Code: PF-06700841 5 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Product Name: Brepocitinib 25 mg
Product Code: PF-06700841 25 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
318Phase 2Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Lithuania;Turkey;Austria;Israel;Russian Federation;Italy;Hungary;Canada;Poland;Romania;Denmark;Georgia;Bulgaria;Netherlands;Germany;Korea, Republic of
5EUCTR2016-003708-29-PL
(EUCTR)
07/06/201726/04/2017Study to evaluate the effectiveness of oral PF-06651600 and PF-06700841 in subjects with moderate to severe ulcerative colitis, a disease characterized by continuous inflammation that is localized to the colonA Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis - Vibrato Moderate to severe Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Ritlecitinib 10 mg
Product Code: PF-06651600 10 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Ritlecitinib 50 mg
Product Code: PF-06651600 50 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Brepocitinib 5 mg
Product Code: PF-06700841 5 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Product Name: Brepocitinib 25 mg
Product Code: PF-06700841 25 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
318Phase 2Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Lithuania;Turkey;Austria;Israel;Russian Federation;Italy;Hungary;Canada;Poland;Romania;Denmark;Georgia;Bulgaria;Netherlands;Germany;Korea, Republic of
6EUCTR2016-003708-29-SK
(EUCTR)
18/04/201724/02/2017Study to evaluate the effectiveness of oral PF-06651600 and PF-06700841 in subjects with moderate to severe ulcerative colitis, a disease characterized by continuous inflammation that is localized to the colonA Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis - Vibrato Moderate to severe Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Ritlecitinib 10 mg
Product Code: PF-06651600 10 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Ritlecitinib 50 mg
Product Code: PF-06651600 50 mg
INN or Proposed INN: PF-06651600
Other descriptive name: PF-06651600-15
Product Name: Brepocitinib 5 mg
Product Code: PF-06700841 5 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Product Name: Brepocitinib 25 mg
Product Code: PF-06700841 25 mg
INN or Proposed INN: PF-06700841
Other descriptive name: PF-06700841-15
Pfizer Inc.NULLNot RecruitingFemale: yes
Male: yes
318Phase 2Serbia;United States;Slovakia;Spain;Ukraine;Lithuania;Turkey;Austria;Israel;Russian Federation;Italy;Hungary;Canada;Poland;Romania;Denmark;Georgia;Bulgaria;Netherlands;Germany;Korea, Republic of